Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (10170)	5/24/1999 12:54:00 PM
From: Edscharp	Read Replies (3) \| Respond to of 17367

FROM MTSL - May 20, 1999 "Investors have responded with approval to XOMA's news of the past several days, with the stock trading as high as $5.69 per share. The company announced the long-awaited conclusion of enrollment in their pivotal Phase III using Neuprex to treat children with meningococcemia. While we believe that one fewer patient died than was outlined in the initial protocol that was authorized by the FDA, we expect that the data will prove positive, and lead to the company's first FDA approval. We estimate that the code will be cracked in July. An interim look at the Phase III hemorrhagic trauma trial, which has already enrolled half ot its anticipated 1,650 patients, will take place this summer as well. Before either of these events, however, we expect a deal for I-PREX to be signed. For these reasons, we are raising our buy limit to $5. For the quarter ended March 31st, XOMA reported a net loss of $13.7 million, or $0.28 per share, compared with a net loss of $10.9 million, or $0.27 per share, for the first quarter in 1998. XOMA is a buy under $5."